Z. Younossi
Epidemiology · 2002–2024
A researcher in the Science corpus: 29 papers; trusts 25 researchers and is trusted by 31 researchers here, as inferred from the citation graph.
Subfields
- Epidemiology — 320 citations into it; #72 of 2,148 by trust here, #34 by citations
- Hepatology — 219 citations into it; #11 of 151 by trust here, #4 by citations
- Endocrinology, Diabetes and Metabolism — 204 citations into it; #122 of 623 by trust here, #37 by citations
- Pathology and Forensic Medicine — 47 citations into it; #22 of 414 by trust here, #12 by citations
- Statistics and Probability — 15 citations into it
Whom Z. Younossi trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
- L. Adams
- W. Viechtbauer
- A. Sanyal
- K. Cusi
- D. Kleiner
- N. Chalasani
- G. Targher
- G. Vernon
- Guido Knapp
- Mustafa S. Ascha
Who trusts Z. Younossi overall
- G. Targher
- R. Loomba
- N. Chalasani
- Megan H. Bair-Merritt
- Y. Sumida
- M. Rinella
- Thomas G. Cotter
- C. Estes
- K. Cusi
- Q. Anstee
Papers from Z. Younossi's perspective
Ordered by how strongly the researchers Z. Younossi trusts endorse each paper. Same corpus, a different order for every researcher.
- Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. (Gastroenterology)
- The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the… (American Journal of Gastroenterology)
- Liver Fibrosis, but no Other Histologic Features, Associates with Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease (Gastroenterology)
- ENDPOINTS AND CLINICAL TRIAL DESIGN FOR NONALCOHOLIC STEATOHEPATITIS (Hepatology)
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease (Hepatology)
- Long‐term follow‐up of patients with NAFLD and elevated liver enzymes (Hepatology)
- Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver‐related mortality (Hepatology)
- EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease (Obesity Facts)
- Of markets and rights: Discourse in the 2008 and 2013 Global Action Plan for the Prevention and Control of Noncommunicable Diseases
- 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The… (Journal of the American College of Cardiology)
Their papers
- Epidemiology of metabolic dysfunction-associated steatotic liver disease (2024) — 672 citations
- The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review (2023) — 2,323 citations
- Advancing the global public health agenda for NAFLD: a consensus statement (2021) — 631 citations
- Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis. (2020) — 864 citations
- Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD (2020) — 634 citations
- The Global Epidemiology of NAFLD and NASH in Patients with type 2 diabetes: A Systematic Review and Meta-analysis. (2019) — 1,901 citations
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. (2019) — 1,024 citations
- Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis (2019) — 1,574 citations
- Non-alcoholic fatty liver disease - A global public health perspective. (2019) — 1,855 citations
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases (2018) — 6,253 citations
- Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease (2017) — 2,091 citations
- Increased risk of mortality by fibrosis stage in non-alcoholic fatty liver disease: Systematic Review and Meta-analysis (2017) — 1,682 citations
- Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes (2016) — 9,590 citations
- The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe (2016) — 1,135 citations
- Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. (2015) — 1,723 citations
- Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009 (2015) — 734 citations
- Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. (2014) — 844 citations
- Sofosbuvir for previously untreated chronic hepatitis C infection. (2013) — 1,908 citations
- The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association (2012) — 2,216 citations
- The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. (2012) — 1,723 citations